Absolute assignment of breast cancer intrinsic molecular subtype.

BACKGROUND Massively parallel gene expression profiling has provided a more objective, molecular-level characterization of breast cancer subtypes. Several bioinformatics tools are available to infer patient subtype from a gene expression profile including the well-studied PAM50. The specific algorithmic methods used in these tools require access to a broad patient dataset. The choice of subtype for an individual is determined relative to all other patients across the panel, making subtypes heavily dependent on the composition of the dataset. Our aim was to develop a bioinformatics approach assigning absolute breast cancer subtypes, independent of dataset composition. METHODS Using a dataset of 4924 breast cancer patients, we defined a new bioinformatics approach: Absolute Intrinsic Molecular Subtyping (AIMS) that assigns subtype from a gene expression profile for an individual sample without the need for a large, diverse, and normalized dataset. We evaluated the agreement of AIMS with PAM50 and compared subtype assignment and prognostic value of the subtypes. We assessed AIMS' robustness using a benchmark set of tests including subtype reproducibility between technologies, gene removal, and normal gene expression contamination, and compared it with PAM50. All statistical tests, except where noted, were two-sided. RESULTS AIMS vastly agreed with PAM50, with 76% and 77% agreement for cross validation and the test set, respectively, and the prognostic capacity of the intrinsic subtypes was preserved. AIMS is fully stable, and its absolute nature enables its use on a wide range of datasets and technologies, including RNA-seq. CONCLUSIONS The instability of a breast cancer subtyping scheme like PAM50 could have important consequences in clinical management of patients. AIMS is a fully stable and robust subtyping scheme that recapitulates PAM50.

[1]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[4]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[6]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[7]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[8]  L. Bernstein,et al.  Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[10]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[12]  Anton Belousov,et al.  Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study , 2014, Clinical Cancer Research.

[13]  M. Hallett,et al.  The prognostic ease and difficulty of invasive breast carcinoma. , 2014, Cell reports.

[14]  Jack Cuzick,et al.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Theodore R Holford,et al.  Molecular and Cellular Pathobiology Transcriptional Profiling Analyses , 2022 .

[16]  Xuesong Lu,et al.  Predicting features of breast cancer with gene expression patterns , 2008, Breast Cancer Research and Treatment.

[17]  Sandrine Dudoit,et al.  Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments , 2010, BMC Bioinformatics.

[18]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[19]  Charles M Perou,et al.  Clinical implementation of the intrinsic subtypes of breast cancer. , 2010, The Lancet. Oncology.

[20]  Simen Myhre,et al.  The importance of gene-centring microarray data. , 2010, The Lancet. Oncology.

[21]  Z. Wen,et al.  Discovery of Molecular Mechanisms of Traditional Chinese Medicinal Formula Si-Wu-Tang Using Gene Expression Microarray and Connectivity Map , 2011, PloS one.

[22]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[23]  Daniel Q. Naiman,et al.  Simple decision rules for classifying human cancers from gene expression profiles , 2005, Bioinform..

[24]  M. Ringnér,et al.  Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.

[25]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[28]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[29]  N. Harbeck,et al.  Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. , 2014, Cancer treatment reviews.

[30]  Zhiyuan Hu,et al.  Systematic Bias in Genomic Classification Due to Contaminating Non-neoplastic Tissue in Breast Tumor Samples , 2011, BMC Medical Genomics.

[31]  Gordon K. Smyth,et al.  A comparison of background correction methods for two-colour microarrays , 2007, Bioinform..

[32]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[33]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[34]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[35]  Lorenzo Ferraro,et al.  Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. , 2010, The American journal of pathology.

[36]  J. Stec,et al.  Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Bertucci,et al.  A refined molecular taxonomy of breast cancer , 2011, Oncogene.

[39]  Federico Ambrogi,et al.  Challenges in projecting clustering results across gene expression-profiling datasets. , 2007, Journal of the National Cancer Institute.